JP2025501629A5 - - Google Patents
Info
- Publication number
- JP2025501629A5 JP2025501629A5 JP2024538674A JP2024538674A JP2025501629A5 JP 2025501629 A5 JP2025501629 A5 JP 2025501629A5 JP 2024538674 A JP2024538674 A JP 2024538674A JP 2024538674 A JP2024538674 A JP 2024538674A JP 2025501629 A5 JP2025501629 A5 JP 2025501629A5
- Authority
- JP
- Japan
- Prior art keywords
- heterocycloalkyl
- alkylene
- cycloalkyl
- heteroaryl
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2021904274 | 2021-12-24 | ||
| AU2021904274A AU2021904274A0 (en) | 2021-12-24 | Compounds | |
| PCT/AU2022/051592 WO2023115166A1 (en) | 2021-12-24 | 2022-12-23 | Compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025501629A JP2025501629A (ja) | 2025-01-22 |
| JP2025501629A5 true JP2025501629A5 (enExample) | 2026-01-07 |
Family
ID=86900852
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024538682A Pending JP2025501630A (ja) | 2021-12-24 | 2022-12-23 | 化合物 |
| JP2024538674A Pending JP2025501629A (ja) | 2021-12-24 | 2022-12-23 | 化合物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024538682A Pending JP2025501630A (ja) | 2021-12-24 | 2022-12-23 | 化合物 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20250074873A1 (enExample) |
| EP (2) | EP4452937A4 (enExample) |
| JP (2) | JP2025501630A (enExample) |
| CN (2) | CN118715204A (enExample) |
| CA (2) | CA3244229A1 (enExample) |
| WO (2) | WO2023115167A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3519816A4 (en) | 2016-09-29 | 2020-05-06 | The Regents of the University of California | CONNECTIONS FOR INCREASING NEURONAL PLASTICITY |
| KR102946120B1 (ko) | 2019-02-27 | 2026-03-30 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 뇌 장애를 치료하기 위한 아제피노-인돌 및 다른 헤테로사이클 |
| IL297861A (en) | 2020-05-08 | 2023-01-01 | Psilera Inc | Novel compositions of matter and pharmaceutical compositions |
| WO2022221415A2 (en) | 2021-04-13 | 2022-10-20 | The Regents Of The University Of California | Tetracyclic compounds for treating brain disorders |
| EP4396162A4 (en) | 2021-09-03 | 2025-11-12 | Alexander Shulgin Res Institute Inc | ASYMMETRIC ALLYL TRYPTAMINES |
| JP2025502615A (ja) | 2021-12-15 | 2025-01-28 | デリックス セラピューティクス，インク． | フェノキシおよびベンジルオキシ置換サイコプラストゲンならびにその使用 |
| CA3238440A1 (en) | 2021-12-30 | 2023-07-06 | Atai Therapeutics, Inc. | Dimethyltryptamine analogues as nitric oxide delivery drugs |
| CA3253725A1 (en) * | 2022-05-20 | 2023-11-23 | Caamtech, Inc. | TRYPTAMINE DERIVATIVES |
| AU2023323907A1 (en) * | 2022-08-11 | 2025-02-20 | Gilgamesh Pharmaceuticals, Inc. | Tryptamines and methods of treating mood disorders |
| CA3265884A1 (en) * | 2022-08-31 | 2024-03-07 | Cybin Irl Limited | TRYPTAMINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE |
| CN121866243A (zh) * | 2023-09-07 | 2026-04-14 | 耶路撒冷希伯来大学伊森姆研究发展有限公司 | 致幻化合物、其制备方法及其用途 |
| WO2025137581A1 (en) * | 2023-12-21 | 2025-06-26 | Atai Therapeutics, Inc. | Novel tetrahydro pyridine substituted indole and azaindoles, compositions of matter and pharmaceutical compositions |
| US12679847B1 (en) | 2025-08-04 | 2026-07-14 | Nalu Bio, Inc. | Aryl-substituted n-alkyl indoles and their use as pharmacologically active agents |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1928892A (en) * | 1991-06-21 | 1993-01-25 | Smithkline Beecham Plc | Tryptamine analogues, their synthesis and their use as 5-ht1-like or 5-ht2 receptor agonists |
| GB9718833D0 (en) * | 1997-09-04 | 1997-11-12 | Merck Sharp & Dohme | Therapeutic agents |
| AU767009B2 (en) * | 1998-12-11 | 2003-10-30 | Virginia Commonwealth University | Selective 5-HT6 receptor ligands |
| SI1379239T1 (sl) * | 2001-03-29 | 2008-02-29 | Lilly Co Eli | N-(2-ariletil)benzilamini, uporabljeni kot antagonisti receptorja 5-ht6 |
| KR20050010512A (ko) * | 2002-06-12 | 2005-01-27 | 스미또모 세이야꾸 가부시키가이샤 | 인돌, 인다졸 및 벤즈아졸류 |
| CA2508290C (en) * | 2002-12-20 | 2017-02-28 | Ciba Specialty Chemicals Holding Inc. | Synthesis of amines and intermediates for the synthesis thereof |
| ES2564804T3 (es) * | 2004-02-12 | 2016-03-29 | Mitsubishi Tanabe Pharma Corporation | Compuesto de indazol y uso farmacéutico del mismo |
| WO2006047032A2 (en) * | 2004-09-27 | 2006-05-04 | Organix, Inc. | Indole compounds useful as serotonin selective agents |
| WO2007046112A1 (en) * | 2005-10-19 | 2007-04-26 | Suven Life Sciences Inc. | Arylthioether tryptamine derivatives as functional 5-ht6 ligands |
| WO2008046155A1 (en) * | 2006-10-20 | 2008-04-24 | Dia-B Tech Limited | Methods for regulating glucose homeostasis and agents therefor |
| US20090318527A1 (en) * | 2008-02-11 | 2009-12-24 | Howard Sard | Indole compounds and methods of use thereof |
| BRPI0916395A2 (pt) * | 2008-07-30 | 2016-02-16 | Ferrer Int | compostos de 1,6-di-hidro-2h-3-oxa-6-aza-as-indaceno |
| US8349898B2 (en) * | 2008-11-18 | 2013-01-08 | Wisconsin Alumni Research Foundation | Sigma-1 receptor ligands and methods of use |
| US8912220B2 (en) * | 2009-08-10 | 2014-12-16 | Galenea Pharmaceuticals | Compounds and methods of use thereof |
| CN103601683B (zh) * | 2010-04-16 | 2016-03-30 | 中国科学院上海药物研究所 | 苯并杂环类化合物及其制备方法和用途 |
| USRE47009E1 (en) * | 2011-02-01 | 2018-08-28 | The Children's Hospital Of Philadelphia | HDAC inhibitors and therapeutic methods using the same |
| LT4084791T (lt) * | 2020-02-18 | 2025-02-25 | Gilgamesh Pharmaceuticals, Inc. | Specifiniai triptaminai, skirti nuotaikos sutrikimams gydyti |
| WO2021179091A1 (en) * | 2020-03-12 | 2021-09-16 | Bright Minds Biosciences Inc. | 3-(2-(aminoethyl)-indol-4-ol derivatives, methods of preparation thereof, and the use as 5-ht2 receptor modulators |
| IL312785B2 (en) * | 2020-05-19 | 2026-06-01 | Cybin Irl Ltd | Deuterated tryptamine derivatives and methods of use |
| US20230014907A1 (en) * | 2020-06-12 | 2023-01-19 | Vertex Pharmaceuticals Incorporated | Inhibitors of apol1 and methods of using same |
| WO2022246554A1 (en) * | 2021-05-26 | 2022-12-01 | Bright Minds Biosciences Inc. | Heterocyclic compounds and methods of preparation thereof |
-
2022
- 2022-12-23 CA CA3244229A patent/CA3244229A1/en active Pending
- 2022-12-23 US US18/723,836 patent/US20250074873A1/en active Pending
- 2022-12-23 EP EP22908928.9A patent/EP4452937A4/en active Pending
- 2022-12-23 JP JP2024538682A patent/JP2025501630A/ja active Pending
- 2022-12-23 CN CN202280091813.9A patent/CN118715204A/zh active Pending
- 2022-12-23 US US18/723,719 patent/US20250101038A1/en active Pending
- 2022-12-23 EP EP22908929.7A patent/EP4452938A4/en active Pending
- 2022-12-23 CN CN202280091811.XA patent/CN118696029A/zh active Pending
- 2022-12-23 WO PCT/AU2022/051593 patent/WO2023115167A1/en not_active Ceased
- 2022-12-23 WO PCT/AU2022/051592 patent/WO2023115166A1/en not_active Ceased
- 2022-12-23 JP JP2024538674A patent/JP2025501629A/ja active Pending
- 2022-12-23 CA CA3244224A patent/CA3244224A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025501630A5 (enExample) | ||
| IL295371A (en) | Psilocyin derivatives as serotonergic psychedelics for the treatment of central nervous system disorders | |
| JP2025501141A5 (enExample) | ||
| JP2023513679A5 (enExample) | ||
| JP7502337B2 (ja) | Ｋｒａｓ ｇ１２ｃインヒビター及びその使用 | |
| JP2023512821A5 (enExample) | ||
| CA2059305C (en) | Hexa-cyclic compound | |
| CN111171047B (zh) | 用于治疗cns障碍的稠合二氢-4h-吡唑并[5,1-c][1,4]噁嗪基化合物 | |
| JP6839104B2 (ja) | ウイルス感染の治療及び予防のための新規な置換アミノチアゾロピリミジンジオン | |
| RU2018115569A (ru) | Оксаспиропроизводное, способ его получения и его применения в лекарственных средствах | |
| TWI543974B (zh) | 苯基－３－氮雜－雙環［３．１．０］己－３－基－甲酮及其作為藥物之用途 | |
| CN119241381A (zh) | 芳基环己基胺衍生物及其在精神障碍的治疗中的用途 | |
| JP2024508922A5 (enExample) | ||
| CA3244224A1 (en) | COMPOUNDS | |
| KR20200083553A (ko) | 치환된 피롤로피리미딘 jak 억제제 및 이의 제조 및 사용 방법 | |
| JP2011511003A5 (enExample) | ||
| JP2023534803A5 (enExample) | ||
| JP2017536399A5 (enExample) | ||
| AU2018342423A1 (en) | Griseofulvin compound and pharmaceutical use thereof | |
| AU2016338602B2 (en) | Cyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide | |
| JP2024534572A5 (enExample) | ||
| AU2010313550A1 (en) | Spirolactam derivatives and uses of same | |
| RU2016144410A (ru) | Позитивные аллостерические модуляторы никотинового рецептора ацетилхолина | |
| JP2016533368A (ja) | ピペラジン誘導体および医薬としてのその使用 | |
| KR20250024908A (ko) | 정신 질환 치료를 위한 피리딘 유도체 |